ReViral is a UK company in clinical stage focusing on the development of novel antiviral therapies against respiratory syncytial virus (RSV). The company's main candidate, sisunatovir, is an oral fusion inhibitor that blocks RSV replication by inhibiting the fusion of the virus with host cells mediated by the RSV-F protein. The drug was certified by the FDA fast track in August 2020.
Currently, sisunatovir has two global phase II clinical studies ongoing: one is the pediatric patient population and the other is the adult stem cell transplant patient population.
In March 2021, Liantuo Biotechnology and ReViral reached an agreement, and the two parties will jointly develop and commercialize sisunatovir in mainland China, Hong Kong, Macao and Singapore. Meanwhile, ReViral will receive a $14 million down payment, and up to $105 million in development and commercial milestone payments.
RSV is a respiratory pathogen that can cause serious and life-threatening lower respiratory tract infection (LRTI) in high-risk populations (such as infants and elderly people). It is estimated that around 64 million people are infected with RSV and about 160,000 people die every year around the world. At present, only AstraZeneca's palivizumab has been approved for the treatment of RSV infection in the world, and the market prospects are broad.
According to Pfizer press release, these projects can bring in $1.5 billion and more annual revenue if successful.
This article is from the Medical Rubik's Cube Info
